Mounjaro in South Africa: clinical guide to availability, cost, and use

The product has become the most discussed weight loss medication of the last two years, in part because the clinical results in published trials were stronger than any previous medication had achieved. It is also one of the more recent arrivals to the South African market.

This guide explains what it actually is, how it differs from other GLP-1 medications, and how to think about it in the context of weight loss treatment.

What it is and how it differs

The product is a brand name for tirzepatide, manufactured by Eli Lilly. Unlike the older medications in the same family, it is not a pure GLP-1 agonist. It activates two receptors at once: the GLP-1 receptor that other products in the category target, and a second receptor called GIP, which is involved in fat metabolism and insulin response.

This dual action is the reason the clinical results have been stronger than older single-receptor medications. In direct comparison trials, average weight loss has been around 20 to 22 percent of starting body weight over 72 weeks, compared to 15 percent for older GLP-1 only products and 2 to 3 percent for placebo. For most patients, this translates to roughly five extra kilograms of loss over a year and a half compared to single-receptor alternatives.

It was originally approved for type 2 diabetes, where it produces similarly strong improvements in blood sugar control. The weight loss effects became apparent during the diabetes trials, and the manufacturer subsequently produced a dedicated weight loss formulation with the same active ingredient at higher therapeutic doses.

Availability in South Africa

The product arrived in South Africa later than competing GLP-1 medications. SAHPRA approval came through in 2024, with commercial availability following over the subsequent months. By 2026, most major South African pharmacies stock at least some doses, though intermittent stockouts have occurred as in other markets.

The dedicated weight loss formulation has been the slower of the two products to arrive. The diabetes formulation is more widely stocked, though it is increasingly prescribed off-label for weight management at appropriate doses.

Availability of the higher dose strengths has been the main constraint. Patients starting treatment generally have no difficulty accessing the lower dose escalation steps, but the highest therapeutic doses can require checking multiple pharmacies or coordinating with your prescriber on alternatives.

Use for weight loss

The product is prescribed for adults meeting the standard clinical criteria for GLP-1 therapy: a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition. The eligibility criteria are essentially identical to other GLP-1 medications.

What differs is the average expected outcome. Where older medications produce 15 percent average loss over a year, this product tends to produce closer to 20 percent. For a patient starting at 100 kg, the difference might be 80 kg at the one-year mark instead of 85 kg. This is a meaningful difference clinically.

The trade-off is that the side effect profile is broadly similar to older medications but the intensity can be slightly higher, particularly during dose escalation. Nausea is the most reported, followed by constipation, mild gastrointestinal discomfort, and the occasional fatigue in the first week of each new dose level. Most patients find the side effects manageable with the same approaches that work for other GLP-1 medications.

Mechanistically, the same general principles apply: reduced appetite, slower gastric emptying, reduced food noise. The dual receptor action adds an additional metabolic benefit that may explain the stronger weight loss results, but the patient experience day to day is largely similar to other GLP-1 therapies.

Cost in South Africa

Pricing for this product in South Africa is generally similar to or slightly higher than older GLP-1 medications. Monthly costs at standard South African pharmacies range from around R2,500 at lower doses to R4,500 or more at the highest therapeutic doses. The exact price varies by pharmacy and by which formulation your doctor prescribes.

The cost per kilogram of weight loss can actually work out favourably compared to older medications, even at a slightly higher monthly price, because the average weight loss is higher. A patient losing 20 kg over a year on this product versus 15 kg on an alternative may be paying more per month but less per kilogram of clinical outcome.

As with other GLP-1 medications, South African medical aids do not generally cover this product for weight loss as of 2026, though coverage is expanding for diabetes patients meeting specific clinical criteria. Bloodwork is usually claimable from medical savings regardless of the medication's coverage status.

For a complete breakdown of total programme costs in South Africa, see our comprehensive cost guide.

How to access it legally

Like all GLP-1 medications in South Africa, this product is prescription-only. It is dispensed at licensed pharmacies on the basis of a script from a registered medical practitioner. The same path applies: a consultation with your GP, a specialist physician, or a registered telemedicine service offering online consultations.

Counterfeit versions have appeared internationally and have been intercepted at South African ports. Some online sellers advertise authentic product at significantly reduced prices, which is almost always a sign that the product is either counterfeit, expired, or has been improperly stored. The medication requires cold storage, and improperly stored product may be ineffective even if the chemical composition is authentic.

The only safe path is a legitimate prescription dispensed at a licensed South African pharmacy.

Choosing the right GLP-1 medication

Patients sometimes arrive at consultations asking for a specific brand. This is understandable given the public profile of some products, but the better framing is to discuss your situation with your doctor and let the clinical decision flow from there.

Several factors influence which specific medication is most appropriate for you:

• Your weight loss goals. Patients with larger amounts of weight to lose often benefit from medications with stronger average outcomes, even at slightly higher cost.
• Your tolerance profile. If you have had significant side effects with one GLP-1 medication, switching to another can sometimes resolve them.
• Availability in your area. A medication that is consistently in stock at your local pharmacy is more practical than one you have to chase across the city every month.
• Your medical history. Some patients have contraindications or risk factors that make one option more appropriate than another.
• Your budget. The differences between medications are real but rarely so large that affordability should be entirely overridden by brand preference.

A good consultation discusses these factors and lands on the medication best suited to your situation. The decision is informed by clinical evidence, not by which brand you read about online.

The bottom line

The product is one of the more effective GLP-1 medications currently available, with clinical results that are roughly 30 percent stronger on average than older single-receptor alternatives. It is available in South Africa with a prescription, though some dose strengths can be harder to source than others.

For patients considering treatment, the right starting point is a proper eligibility assessment and consultation. The choice of specific medication is a clinical decision that depends on your situation, not on the brand name you walked in asking about.